"Sao Paulo-Minas Gerais Center for Chagas Disease Treatment (SaMiTrop)"

“圣保罗-米纳斯吉拉斯州恰加斯病治疗中心 (SaMiTrop)”

• 批准号: 10592351
• 负责人: Ester Cerdeira Sabino
• 金额: $ 38.87万
• 依托单位: FUNDACAO FACULDADE DE MEDICINA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10592351
• 关键词: Antibodies; Area; Articulation; Artificial Intelligence; Benznidazole; Biological Markers; Cardiac; Cardiomyopathies; Central America; Chagas Disease; Chronic; Clinical; Data; Data Collection; Diagnosis; Disease Marker; Enrollment; Etiology; Health system; Healthcare Systems; Heart Diseases; Imaging Techniques; Inflammation; Knowledge; Latin America; Lesion; Magnetic Resonance; Maps; Measures; Methodology; Methods; Morbidity - disease rate; Myocardial; Myocardial tissue; Natural History; Patients; Persons; Plasma; Positron-Emission Tomography; Primary Health Care; Process; Prospective cohort; Protocols documentation; Registries; Research; Research Personnel; Sampling; Surrogate Markers; Testing; Treatment Efficacy; Tropical Medicine; Trypanocidal Agents; Trypanosoma cruzi; biomarker identification; biomarker panel; biomarker validation; candidate marker; clinically relevant; cohort; diagnostic strategy; digital health; efficacy validation; follow-up; health care availability; health service use; heart imaging; implementation framework; implementation science; improved; mortality; neglect; patient-level barriers; prospective; response; success; tool

ABSTRACT Chagas disease (CD) remains one of the most neglected illnesses in the world, with estimates indicating 5.7 million infected people in Latin and Central America. Currently, there are many barriers that patients with CD have to overcome to obtain a diagnosis, adequate treatment, and appropriate follow-up. One of the main ones is the high rate of underdiagnosis and consequently of patients treated. It is estimated that less than 10% of patients are diagnosed and that less than 1% are treated. Furthermore, to date, there is no "reliable" method that allows measuring therapeutic efficacy. During the last 15 years, researchers from the São Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) have developed numerous projects that have evidenced the high number of patients in an endemic area in the north of the State of Minas Gerais, in addition to providing valuable information on the natural history of CD, the rate of progression to cardiomyopathy and its relationship with antibody levels. A great key to the success of such initiatives has been their strategic articulation with primary health care, which has made it possible to have large cohorts of patients accompanied for more than 10 years. Therefore, it is intended in this project to apply all this knowledge and articulation to identify methodologies and tools that allow overcoming existing barriers. The results obtained will make it possible to increase the number of diagnosed patients to whom treatment will be offered and identify strategies and biomarkers that make it possible to improve patient follow-up and help evaluate new treatment candidates.

抽象的 查加斯病 (CD) 仍然是世界上最被忽视的疾病之一，估计有 5.7 目前，拉丁美洲和中美洲的感染者有很多障碍。 为了获得诊断、充分的治疗和适当的随访，必须克服的主要问题之一是。 诊断不足率很高，因此接受治疗的患者人数估计不到 10%。 被诊断出来并且接受治疗的人不到 1% 此外，迄今为止，还没有“可靠”的方法可以做到这一点。 在过去 15 年中，圣保罗-米纳斯吉拉斯州热带研究中心的研究人员测量了治疗效果。 医学研究中心 (SaMi-Trop) 开发了许多项目，证明了 米纳斯吉拉斯州北部流行区的患者，除了提供宝贵的 有关 CD 自然史、进展为心肌病的速率及其与疾病的关系的信息 此类举措成功的一个重要关键是其与主要目标的战略衔接。 医疗保健，这使得陪伴大量患者超过 10 年成为可能。 因此，本项目旨在应用所有这些知识和阐述来确定方法和 克服现有障碍的工具所获得的结果将有可能增加数量。 将接受治疗的确诊患者的数量，并确定治疗策略和生物标志物 可以改善患者随访并帮助评估新的治疗方案。